Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB lowered its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 10.6% in the fourth quarter, HoldingsChannel reports. The firm owned 104,117 shares of the company’s stock after selling 12,398 shares during the quarter. Handelsbanken Fonder AB’s holdings in Henry Schein were worth $7,883,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Xponance Inc. grew its holdings in shares of Henry Schein by 2.1% in the third quarter. Xponance Inc. now owns 21,839 shares of the company’s stock valued at $1,622,000 after purchasing an additional 443 shares in the last quarter. Everett Harris & Co. CA lifted its stake in Henry Schein by 29.1% in the fourth quarter. Everett Harris & Co. CA now owns 104,677 shares of the company’s stock worth $7,925,000 after acquiring an additional 23,622 shares during the last quarter. Sprucegrove Investment Management Ltd. lifted its stake in Henry Schein by 14.2% in the fourth quarter. Sprucegrove Investment Management Ltd. now owns 220,491 shares of the company’s stock worth $16,693,000 after acquiring an additional 27,500 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Henry Schein by 215.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 74,251 shares of the company’s stock worth $5,622,000 after acquiring an additional 50,723 shares during the last quarter. Finally, Caxton Associates LP lifted its stake in Henry Schein by 80.8% in the third quarter. Caxton Associates LP now owns 18,991 shares of the company’s stock worth $1,410,000 after acquiring an additional 8,486 shares during the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Stock Up 0.6 %

HSIC stock opened at $73.21 on Thursday. The company has a fifty day moving average price of $74.29 and a 200 day moving average price of $72.43. Henry Schein, Inc. has a 12 month low of $60.01 and a 12 month high of $85.39. The company has a market cap of $9.41 billion, a price-to-earnings ratio of 23.24, a price-to-earnings-growth ratio of 1.80 and a beta of 0.87. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.67 and a quick ratio of 1.00.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.66 EPS for the quarter, missing the consensus estimate of $0.70 by ($0.04). Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The business had revenue of $3.02 billion during the quarter, compared to analysts’ expectations of $3 billion. During the same quarter last year, the company earned $1.21 EPS. The firm’s revenue for the quarter was down 10.5% compared to the same quarter last year. Sell-side analysts expect that Henry Schein, Inc. will post 5.07 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Evercore ISI lifted their price target on shares of Henry Schein from $79.00 to $83.00 and gave the stock an “in-line” rating in a research note on Wednesday, February 28th. Jefferies Financial Group lifted their price target on shares of Henry Schein from $74.00 to $81.00 and gave the stock a “hold” rating in a research note on Wednesday, March 6th. TheStreet upgraded shares of Henry Schein from a “c+” rating to a “b-” rating in a research note on Monday, February 26th. Piper Sandler lifted their price target on shares of Henry Schein from $78.00 to $86.00 and gave the stock an “overweight” rating in a research note on Monday, February 26th. Finally, SVB Leerink initiated coverage on shares of Henry Schein in a research report on Monday, February 26th. They set a “market perform” rating and a $78.00 price objective for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $81.09.

Insider Activity at Henry Schein

In related news, Vice Chairman James P. Breslawski sold 2,907 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the sale, the insider now owns 209,562 shares in the company, valued at approximately $15,585,125.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Henry Schein news, CEO Bradford C. Connett sold 6,430 shares of the business’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total value of $477,620.40. Following the transaction, the chief executive officer now directly owns 73,108 shares of the company’s stock, valued at approximately $5,430,462.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the completion of the transaction, the insider now directly owns 209,562 shares in the company, valued at $15,585,125.94. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.